You can buy or sell Albireo Pharma and other stocks, options, ETFs, and crypto commission-free!
Albireo Pharma, Inc. Common Stock, also called Albireo Pharma, is a pharmaceutical company, which engages in the development and commercialization of bile acid modulators for the treatment of orphan pediatric liver diseases and gastrointestinal disorders. Read More Its product pipeline includes A4250, Elobixibat, and A3384. The company was founded by Jan Peter Mattsson and Per-Göran Gillberg on December 8, 2003 and is headquartered in Boston, MA.
52 Week High
52 Week Low
Yahoo FinanceMay 2
Albireo to Report First Quarter 2019 Financial Results and Host Conference Call and Webcast
BOSTON, May 02, 2019 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that management will host a conference call and live audio webcast at 10 a.m. EDT on May 9, 2019, to review the first quarter ended March 31, 2019, financial results and provide a business update. To access the live conference call by phone, dial 877-407-0792 (domestic) or 201-689-8263 (international), and provide the access c...
-$1.32 per share
-$1.39 per share